The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10858 malaria professionals are enjoying the free benefits of MalariaWorld today

proteasome inhibition

Plasmodium berghei K13 Mutations Mediate In Vivo Artemisinin Resistance That Is Reversed by Proteasome Inhibition

November 11, 2020 - 14:33 -- Open Access
Author(s): 
Simwela NV, Stokes BH, Aghabi D, Bogyo M, Fidock DA, Waters AP
Reference: 
mBio. 2020 Nov 10;11(6):e02312-20

The recent emergence of Plasmodium falciparum parasite resistance to the first line antimalarial drug artemisinin is of particular concern. Artemisinin resistance is primarily driven by mutations in the P. falciparum K13 protein, which enhance survival of early ring-stage parasites treated with the artemisinin active metabolite dihydroartemisinin in vitro and associate with delayed parasite clearance in vivo However, association of K13 mutations with in vivo artemisinin resistance has been problematic due to the absence of a tractable model.

Subscribe to RSS - proteasome inhibition